## Michael R Jaff

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4202125/publications.pdf

Version: 2024-02-01

208 papers 13,454 citations

51 h-index 22808 112 g-index

281 all docs

281 does citations

times ranked

281

10066 citing authors

#	Article	IF	CITATIONS
1	Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study. American Heart Journal, 2022, 251, 43-53.	1.2	59
2	Cost-effectiveness of a paclitaxel-eluting stent (Eluvia) compared to Zilver PTX for endovascular femoropopliteal intervention. Journal of Medical Economics, 2022, 25, 880-887.	1.0	5
3	Endovascular Intervention for the Treatment of Trans-Atlantic Inter-Society Consensus (TASC) D Femoropopliteal Lesions: A Systematic Review and Meta-Analysis. Cardiovascular Revascularization Medicine, 2021, 22, 52-65.	0.3	14
4	Clinical Impact of Contralateral Carotid Occlusion in Patients Undergoing Carotid Artery Revascularization. Journal of the American College of Cardiology, 2021, 77, 835-844.	1.2	9
5	Time-Restricted Salutary Effects of Blood Flow Restoration on Venous Thrombosis and Vein Wall Injury in Mouse and Human Subjects. Circulation, 2021, 143, 1224-1238.	1.6	21
6	Modern multidisciplinary team approach is crucial in treatment for critical limb threatening ischemia. Journal of Cardiovascular Surgery, 2021, 62, 124-129.	0.3	3
7	Analysis of Costs and Payments for Inferior Vena Cava Filter Retrieval in the Medicare Population. Journal of Vascular and Interventional Radiology, 2021, 32, 1164-1169.	0.2	1
8	Case 30-2021: A 47-Year-Old Man with Recurrent Unilateral Head and Neck Pain. New England Journal of Medicine, 2021, 385, 1317-1325.	13.9	0
9	Objective Outcome Measures for Trials in Patients With Chronic Limb-Threatening Ischemia Across 2 Decades. JACC: Cardiovascular Interventions, 2021, 14, 2584-2597.	1.1	O
10	Paclitaxel-Coated Zilver PTX Drug-Eluting Stent Treatment Does Not Result in Increased Long-Term All-Cause Mortality Compared to Uncoated Devices. CardioVascular and Interventional Radiology, 2020, 43, 8-19.	0.9	47
11	Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2020, 8, 8-23.e18.	0.9	55
12	Response to Gwozdz and colleagues. Vascular Medicine, 2020, 25, 90-91.	0.8	0
13	American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Advances, 2020, 4, 4693-4738.	2.5	636
14	Paclitaxel Drug-Coated Balloon Angioplasty Suppresses Progression and Inflammation of Experimental Atherosclerosis in Rabbits. JACC Basic To Translational Science, 2020, 5, 685-695.	1.9	18
15	Three-Year Results of the IN.PACT SFA Japan Trial Comparing Drug-Coated Balloons With Percutaneous Transluminal Angioplasty. Journal of Endovascular Therapy, 2020, 27, 946-955.	0.8	16
16	Mortality and Paclitaxel-Coated Devices. Circulation, 2020, 141, 1859-1869.	1.6	122
17	<scp>SCAI</scp> guidelines on device selection in <scp>Aortoâ€liac</scp> arterial interventions. Catheterization and Cardiovascular Interventions, 2020, 96, 915-929.	0.7	21
18	Digital Subtraction Angiography Prior to an Amputation for Critical Limb Ischemia (CLI): An Expert Recommendation Statement From the CLI Global Society to Optimize Limb Salvage. Journal of Endovascular Therapy, 2020, 27, 540-546.	0.8	9

#	Article	IF	CITATIONS
19	Three-Year Sustained Clinical Efficacy of Drug-Coated Balloon Angioplasty in a Real-World Femoropopliteal Cohort. Journal of Endovascular Therapy, 2020, 27, 693-705.	0.8	34
20	SCAI publications committee manual of standard operating procedures. Catheterization and Cardiovascular Interventions, 2020, 96, 145-155.	0.7	12
21	Outcomes of catheter-directed versus systemic thrombolysis for the treatment of pulmonary embolism: A real-world analysis of national administrative claims. Vascular Medicine, 2020, 25, 334-340.	0.8	23
22	Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis. Blood Advances, 2020, 4, 1539-1553.	2.5	15
23	Three-Year Efficacy and Safety of the MisagoÂPeripheral Stent for Superficial Femoral Artery Disease: Final Results from the OSPREY Trial. Journal of Vascular and Interventional Radiology, 2020, 31, 978-985.	0.2	2
24	Peripheral vascular manifestation in patients receiving an amphetamine analog: A case series. Vascular Medicine, 2019, 24, 50-55.	0.8	10
25	Expanding opportunities to understand quality and outcomes of peripheral vascular interventions: The ACC NCDR PVI Registry. American Heart Journal, 2019, 216, 74-81.	1.2	10
26	Relationships between the use of pharmacomechanical catheter-directed thrombolysis, sonographic findings, and clinical outcomes in patients with acute proximal DVT: Results from the ATTRACT Multicenter Randomized Trial. Vascular Medicine, 2019, 24, 442-451.	0.8	35
27	Cost-Effectiveness of Pharmacomechanical Catheter-Directed Thrombolysis Versus Standard Anticoagulation in Patients With Proximal Deep Vein Thrombosis. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005659.	0.9	17
28	Propensity Score–Adjusted Comparison of Long-Term Outcomes Among Revascularization Strategies for Critical Limb Ischemia. Circulation: Cardiovascular Interventions, 2019, 12, e008097.	1.4	16
29	Mortality Assessment of Paclitaxel-Coated Balloons. Circulation, 2019, 140, 1145-1155.	1.6	59
30	Total IN.PACT drug-coated balloon initiative reporting pooled imaging and propensity-matched cohorts. Journal of Vascular Surgery, 2019, 70, 1177-1191.e9.	0.6	12
31	Dissections After Infrainguinal Percutaneous Transluminal Angioplasty: A Systematic Review and Current State of Clinical Evidence. Journal of Endovascular Therapy, 2019, 26, 479-489.	0.8	25
32	Paclitaxel and Mortality: The Dose Argument Is Critical. Journal of Endovascular Therapy, 2019, 26, 467-470.	0.8	24
33	iCAST Balloon-Expandable Covered Stent for Iliac Artery Lesions: 3-Year Results from the iCARUS Multicenter Study. Journal of Vascular and Interventional Radiology, 2019, 30, 822-829.e4.	0.2	13
34	Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions. Circulation: Cardiovascular Interventions, 2019, 12, e007702.	1.4	120
35	Vascular Teams in PeripheralÂVascularÂDisease. Journal of the American College of Cardiology, 2019, 73, 2477-2486.	1.2	32
36	Drug-Coated Balloon Treatment forÂFemoropopliteal Artery Disease. JACC: Cardiovascular Interventions, 2019, 12, 484-493.	1.1	37

#	Article	IF	Citations
37	Ultrasound-assisted versus conventional catheter-directed thrombolysis for acute pulmonary embolism: A multicenter comparison of patient-centered outcomes. Vascular Medicine, 2019, 24, 241-247.	0.8	39
38	Balloon-Expandable Vascular Covered Stent in the Treatment of Iliac Artery Occlusive Disease: 9-Month Results from the BOLSTER Multicenter Study. Journal of Vascular and Interventional Radiology, 2019, 30, 836-844.e1.	0.2	13
39	One-Year Results of the LIBERTY 360 Study: Evaluation of Acute and Midterm Clinical Outcomes of Peripheral Endovascular Device Interventions. Journal of Endovascular Therapy, 2019, 26, 143-154.	0.8	35
40	Association of Survival With Femoropopliteal Artery Revascularization With Drug-Coated Devices. JAMA Cardiology, 2019, 4, 332.	3.0	178
41	Drugâ€coated balloon versus uncoated percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal artery: 2â€year results of the MDTâ€2113 SFA Japan randomized trial. Catheterization and Cardiovascular Interventions, 2019, 93, 664-672.	0.7	39
42	Strength of Evidence Underlying the American Heart Association/American College of Cardiology Guidelines on Endovascular and Surgical Treatment of Peripheral Vascular Disease:. Circulation: Cardiovascular Interventions, 2019, 12, e007244.	1.4	16
43	Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain. Circulation: Cardiovascular Interventions, 2019, 12, e007730.	1.4	10
44	Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis. Circulation, 2019, 139, 1162-1173.	1.6	196
45	Usefulness of a Computerized Reminder System to Improve Inferior Vena Cava Filter Retrieval and Complications. American Journal of Cardiology, 2019, 123, 348-353.	0.7	8
46	Changes in treatment and outcomes after creation of a pulmonary embolism response team (PERT), a 10-year analysis. Journal of Thrombosis and Thrombolysis, 2019, 47, 31-40.	1.0	94
47	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Circulation, 2018, 137, 961-972.	1.6	368
48	Longâ $\in$ term clinical and quality of life outcomes after stenting of femoropopliteal artery stenosis: $3$ â $\in$ year results from the STROLL study. Catheterization and Cardiovascular Interventions, 2018, 92, 106-114.	0.7	16
49	Cardiopulmonary Exercise Testing in Patients Following Massive and Submassive Pulmonary Embolism. Journal of the American Heart Association, 2018, 7, .	1.6	48
50	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Journal of the American College of Cardiology, 2018, 71, 1021-1034.	1.2	211
51	Public Health Impact of the Centers for Medicare and Medicaid Services Decision on Pass-Through Add-On Payments for Drug-Coated Balloons. JACC: Cardiovascular Interventions, 2018, 11, 496-499.	1.1	7
52	Nine-Month Outcomes of the DURABILITY Iliac Study on Self-Expanding Stents for Symptomatic Peripheral Artery Disease. Annals of Vascular Surgery, 2018, 51, 37-47.	0.4	4
53	SCAI consensus guidelines for device selection in femoralâ€popliteal arterial interventions. Catheterization and Cardiovascular Interventions, 2018, 92, 124-140.	0.7	122
54	Treatment of submassive and massive pulmonary embolism: a clinical practice survey from the second annual meeting of the Pulmonary Embolism Response Team Consortium. Journal of Thrombosis and Thrombolysis, 2018, 46, 39-49.	1.0	19

#	Article	lF	CITATIONS
55	Novel Nitinol Stent for Lesions up to 24 cm in the Superficial Femoral and Proximal Popliteal Arteries: 24-Month Results From the TIGRIS Randomized Trial. Journal of Endovascular Therapy, 2018, 25, 68-78.	0.8	23
56	Why Did I Not Think of This? Water Therapy for PAD! (Invited Commentary). Annals of Vascular Surgery, 2018, 49, 7-8.	0.4	1
57	Carotid Stent Fractures Are Not Associated With Adverse Events. Circulation, 2018, 137, 49-56.	1.6	11
58	Stellarex drugâ€coated balloon for treatment of femoropopliteal arterial diseaseâ€"The <scp>ILLUMENATE</scp> Global Study: 12â€Month results from a prospective, multicenter, singleâ€arm study. Catheterization and Cardiovascular Interventions, 2018, 91, 497-504.	0.7	40
59	Extra-corporeal membrane oxygenation and outcomes in massive pulmonary embolism: Two eras at an urban tertiary care hospital. Vascular Medicine, 2018, 23, 60-64.	0.8	25
60	One-Year Outcomes Following Directional Atherectomy of Popliteal Artery Lesions: Subgroup Analysis of the Prospective, Multicenter DEFINITIVE LE Trial. Journal of Endovascular Therapy, 2018, 25, 100-108.	0.8	21
61	Nitinol Self-Expanding Stents for the Treatment of Obstructive Superficial Femoral Artery Disease: Three-Year Results of the RELIABLE Japanese Multicenter Study. Annals of Vascular Diseases, 2018, 11, 324-334.	0.2	8
62	Sustainable Antirestenosis Effect With a Low-Dose Drug-Coated Balloon. JACC: Cardiovascular Interventions, 2018, 11, 2357-2364.	1.1	52
63	A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet, The, 2018, 392, 1541-1551.	6.3	196
64	Drug-Coated Balloon Treatment of Femoropopliteal Lesions Typically Excluded From Clinical Trials: 12-Month Findings From the IN.PACT Global Study. Journal of Endovascular Therapy, 2018, 25, 673-682.	0.8	21
65	Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease. Circulation: Cardiovascular Interventions, 2018, 11, e005654.	1.4	51
66	Design Strategies for Global Clinical Trials of Endovascular Devices for Critical Limb Ischemia (CLI) ― A Joint USA-Japanese Perspective ―. Circulation Journal, 2018, 82, 2233-2239.	0.7	7
67	Adventitial Drug Delivery of Dexamethasone to Improve Primary Patency in the Treatment of Superficial Femoral and Popliteal Artery Disease. JACC: Cardiovascular Interventions, 2018, 11, 921-931.	1.1	18
68	Contemporary Management and Outcomes of Patients with Massive and Submassive Pulmonary Embolism. American Journal of Medicine, 2018, 131, 1506-1514.e0.	0.6	79
69	Response by Schneider et al to Letter Regarding Article, "Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial― Circulation: Cardiovascular Interventions, 2018, 11, e006699.	1.4	12
70	Response by Weinberg et al to Letter Regarding Article, "Carotid Stent Fractures Are Not Associated With Adverse Events: Results From the ACT-1 Multicenter Randomized Trial (Carotid Angioplasty and) Tj ETQqC	0 0 0 rgBT /0 1.6	Overlock 10 T 1
71	2676-2677.  Cerebrovascular fibromuscular dysplasia. Neurology: Clinical Practice, 2017, 7, 225-236.	0.8	24
72	The Italian stallions of <scp>CLI</scp> "value care―delivery. Catheterization and Cardiovascular Interventions, 2017, 89, 921-922.	0.7	0

#	Article	IF	Citations
73	A Quantitative Angiographic Comparison of Restenotic Tissue Following Placement of Drug-Eluting Stents and Bare Metal Stents in Symptomatic Patients With Femoropopliteal Disease. Journal of Endovascular Therapy, 2017, 24, 499-503.	0.8	6
74	Carotid Artery Stenting Versus Endarterectomy for Stroke Prevention. Journal of the American College of Cardiology, 2017, 69, 2266-2275.	1.2	122
75	Results From the VISIBILITY Iliac Study: Primary and Cohort Outcomes at 9 Months. Journal of Endovascular Therapy, 2017, 24, 342-348.	0.8	6
76	Stent placement in the superficial femoral and proximal popliteal arteries with the innova selfâ€expanding bare metal stent system. Catheterization and Cardiovascular Interventions, 2017, 89, 1069-1077.	0.7	15
77	Patientâ€level metaâ€analysis of 999 claudicants undergoing primary femoropopliteal nitinol stent implantation. Catheterization and Cardiovascular Interventions, 2017, 89, 1250-1256.	0.7	20
78	Impact of Pulmonary Arterial Clot Location on Pulmonary Embolism Treatment and Outcomes (90ÂDays). American Journal of Cardiology, 2017, 119, 802-807.	0.7	21
79	Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease. JACC: Cardiovascular Interventions, 2017, 10, 2113-2123.	1.1	60
80	Endovascular Interventions for Femoropopliteal Peripheral Artery Disease: A Network Meta-Analysis of Current Technologies. Journal of Vascular and Interventional Radiology, 2017, 28, 1617-1627.e1.	0.2	42
81	The CLOSER trial: a multiâ€center study on the clinical safety and effectiveness of Closer <sup>TM</sup> VSS, a novel resorbable transfemoral vascular access sealing system. Catheterization and Cardiovascular Interventions, 2017, 90, 798-805.	0.7	1
82	Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	180
83	Prevalence of Intracranial Aneurysm in Women With Fibromuscular Dysplasia. JAMA Neurology, 2017, 74, 1081.	4.5	54
84	SCAI appropriate use criteria for peripheral arterial interventions: An update. Catheterization and Cardiovascular Interventions, 2017, 90, E90-E110.	0.7	69
85	Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. New England Journal of Medicine, 2017, 377, 2240-2252.	13.9	557
86	Stent Versus Scalpel in PeripheralÂArteryÂDisease. JACC: Cardiovascular Interventions, 2017, 10, 2332-2333.	1.1	0
87	A Measured Approach to Vena Cava Filter Use—Respect Rather Than Regret. JAMA Cardiology, 2017, 2, 5.	3.0	5
88	Comparison of Inferior Vena Cava Filters Placed at the Bedside via Intravenous Ultrasound Guidance Versus Fluoroscopic Guidance. Annals of Vascular Surgery, 2017, 39, 250-255.	0.4	7
89	Anticoagulation Is Associated with Decreased Inferior Vena Cava Filter-Related Complications in Patients with Metastatic Carcinoma. American Journal of Medicine, 2017, 130, 77-82.e1.	0.6	12
90	Key Concepts in Critical Limb Ischemia: Selected Proceedings from the 2015 Vascular Interventional Advances Meeting. Annals of Vascular Surgery, 2017, 38, 191-205.	0.4	11

#	Article	IF	Citations
91	SUPERB final 3â€year outcomes using interwoven nitinol biomimetic supera stent. Catheterization and Cardiovascular Interventions, 2017, 89, 1259-1267.	0.7	92
92	Angiographic classification of patterns of restenosis following femoropopliteal artery intervention: A proposed scoring system. Catheterization and Cardiovascular Interventions, 2017, 90, 639-646.	0.7	5
93	Peripheral artery disease: breakthroughs in techniques and treatments. Journal of Cardiovascular Surgery, 2017, 58, 689.	0.3	0
94	Prioritization of treatments for lower extremity peripheral artery disease in low- and middle-income countries. International Angiology, 2017, 36, 203-215.	0.4	13
95	Dissection and Aneurysm in Patients WithÂFibromuscular Dysplasia. Journal of the American College of Cardiology, 2016, 68, 176-185.	1.2	168
96	Percutaneous Therapies for Peripheral Artery Disease. Circulation, 2016, 134, 2008-2027.	1.6	78
97	How to Treat Critical Limb Ischemia. JACC: Cardiovascular Interventions, 2016, 9, 2566-2567.	1.1	0
98	Favorable Angiographic Outcome AfterÂTreatment of Infrapopliteal Lesions With Drug-Coated Balloons Without Clinical Benefit. JACC: Cardiovascular Interventions, 2016, 9, 1081-1082.	1.1	2
99	One-year outcomes of the U.S. and Japanese regulatory trial of the Misago stent for treatment of superficial femoral artery disease (OSPREY study). Journal of Vascular Surgery, 2016, 63, 370-376.e1.	0.6	21
100	Vascular Specialist Response to Medicare Evidence Development Coverage Advisory Committee (MEDCAC) Panel on Peripheral Artery Disease of the Lower Extremities. Journal of the American College of Radiology, 2016, 13, 1296-1301.	0.9	1
101	Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery. Circulation, 2016, 133, 1472-1483.	1.6	426
102	Case 13-2016. New England Journal of Medicine, 2016, 374, 1671-1680.	13.9	8
103	Comparative Effectiveness of Carotid Artery Stenting Versus Carotid Endarterectomy Among Medicare Beneficiaries. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 275-285.	0.9	24
104	Critical Limb Ischemia. Journal of the American College of Cardiology, 2016, 68, 2002-2015.	1.2	127
105	<scp>SCAI/SVM</scp> expert consensus statement on Carotid Stenting: Training and credentialing for Carotid Stenting. Catheterization and Cardiovascular Interventions, 2016, 87, 188-199.	0.7	25
106	Intersocietal Accreditation Commission Accreditation Status of Outpatient Cerebrovascular Testing Facilities Among Medicare Beneficiaries. Journal of Ultrasound in Medicine, 2016, 35, 1957-1965.	0.8	10
107	Design and Rationale of the Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BESTâ€CLI) Trial. Journal of the American Heart Association, 2016, 5, .	1.6	158
108	Cost-Effectiveness of Endovascular Femoropopliteal Intervention Using Drug-Coated BalloonsÂVersus Standard Percutaneous Transluminal Angioplasty. JACC: Cardiovascular Interventions, 2016, 9, 2343-2352.	1.1	50

#	Article	IF	Citations
109	Can Inferior Vena Cava Filters Change Their Struts?. JACC: Cardiovascular Interventions, 2016, 9, 2449-2451.	1.1	O
110	Vascular specialist response to medicare evidence development coverage advisory committee (MEDCAC) panel on peripheral artery disease of the lower extremities. Catheterization and Cardiovascular Interventions, 2016, 87, 1181-1186.	0.7	1
111	Bioresorbable Everolimus-Eluting VascularÂScaffold for Patients With PeripheralÂArtery Disease (ESPRIT I). JACC: Cardiovascular Interventions, 2016, 9, 1178-1187.	1.1	30
112	Endovascular therapy for advanced post-thrombotic syndrome: Proceedings from a multidisciplinary consensus panel. Vascular Medicine, 2016, 21, 400-407.	0.8	44
113	Research Priorities in Submassive Pulmonary Embolism: Proceedings from a Multidisciplinary Research Consensus Panel. Journal of Vascular and Interventional Radiology, 2016, 27, 787-794.	0.2	26
114	Vascular specialist response to Medicare Evidence Development Coverage Advisory Committee (MEDCAC) panel on peripheral artery disease of the lower extremities. Vascular Medicine, 2016, 21, 281-286.	0.8	7
115	A Multidisciplinary Pulmonary Embolism Response Team. Chest, 2016, 150, 384-393.	0.4	195
116	Randomized Trial of Stent versus Surgery for Asymptomatic Carotid Stenosis. New England Journal of Medicine, 2016, 374, 1011-1020.	13.9	486
117	The LIBERTY study: Design of a prospective, observational, multicenter trial to evaluate the acute and long-term clinical and economic outcomes of real-world endovascular device interventions in treating peripheral artery disease. American Heart Journal, 2016, 174, 14-21.	1.2	20
118	A single stent strategy in patients with lifestyle limiting claudication: 3â€year results from the Durability II trial. Catheterization and Cardiovascular Interventions, 2015, 86, 164-170.	0.7	47
119	An update on methods for revascularization and expansion of the TASC lesion classification to include belowâ€theâ€knee arteries: A supplement to the interâ€society consensus for the management of peripheral arterial disease (TASC II): The TASC steering committee*. Catheterization and Cardiovascular Interventions, 2015, 86, 611-625.	0.7	76
120	Thrombectomy using suction filtration and venoâ€venous bypass: Single center experience with a novel device. Catheterization and Cardiovascular Interventions, 2015, 86, E81-7.	0.7	109
121	Relationship Between Physician and Hospital Procedure Volume and Mortality After Carotid Artery Stenting Among Medicare Beneficiaries. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, S81-9.	0.9	19
122	Blood Accessibility to Fibrin in Venous Thrombosis is Thrombus Age-Dependent and Predicts Fibrinolytic Efficacy: An In Vivo Fibrin Molecular Imaging Study. Theranostics, 2015, 5, 1317-1327.	4.6	21
123	An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Annals of Vascular Diseases, 2015, 8, 343-357.	0.2	122
124	Asynchronous vascular consultation via electronic methods: A feasibility pilot. Vascular Medicine, 2015, 20, 551-556.	0.8	27
125	Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions. Journal of the American College of Cardiology, 2015, 66, 2329-2338.	1.2	325
126	A Comparison of Clinical Outcomes for Diabetic and Nondiabetic Patients Following Directional Atherectomy in the DEFINITIVE LE Claudicant Cohort. Journal of Endovascular Therapy, 2015, 22, 701-711.	0.8	20

#	Article	IF	CITATIONS
127	The THUNDER Trial Results. JACC: Cardiovascular Interventions, 2015, 8, 109-110.	1.1	O
128	A Comparison of Patients Diagnosed With Pulmonary Embolism Who Are ≥65ÂYears With Patients & lt;65ÂYears. American Journal of Cardiology, 2015, 115, 681-686.	0.7	15
129	Evaluation and Treatment of Patients With Lower Extremity Peripheral ArteryÂDisease. Journal of the American College of Cardiology, 2015, 65, 931-941.	1.2	269
130	Supervised Exercise, Stent Revascularization, or MedicalÂTherapy forÂClaudication Due to Aortoiliac Peripheral Artery Disease. Journal of the American College of Cardiology, 2015, 65, 999-1009.	1.2	225
131	Outcomes After Carotid Artery Stenting in Medicare Beneficiaries, 2005 to 2009. JAMA Neurology, 2015, 72, 276.	4.5	66
132	Wire-Interwoven Nitinol Stent Outcome in the Superficial Femoral and Proximal Popliteal Arteries. Circulation: Cardiovascular Interventions, $2015, 8, .$	1.4	126
133	The Society for Vascular Medicine: The first quarter century. Vascular Medicine, 2015, 20, 60-68.	0.8	5
134	The Role of Sonographic Imaging to Assess the Pathophysiology of Cording in Patients Treated for Breast Cancer. Journal of Diagnostic Medical Sonography, 2015, 31, 276-281.	0.1	1
135	Response to Letter Regarding Article, " ⟨sup⟩ 18⟨/sup⟩ F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Enables the Detection of Recurrent Same-Site Deep Vein Thrombosis by Illuminating Recently Formed, Neutrophil-Rich Thrombusâ€; Circulation, 2015, 131, e531-2.	1.6	0
136	Safety and Effectiveness of Stent Placement for Iliofemoral Venous Outflow Obstruction. Circulation: Cardiovascular Interventions, 2015, 8, e002772.	1.4	186
137	An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries. Journal of Endovascular Therapy, 2015, 22, 663-677.	0.8	152
138	An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Vascular Medicine, 2015, 20, 465-478.	0.8	127
139	Anti-platelet and anti-hypertension medication use in patients with fibromuscular dysplasia: Results from the United States Registry for Fibromuscular Dysplasia. Vascular Medicine, 2015, 20, 447-453.	0.8	26
140	A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism. JACC: Cardiovascular Interventions, 2015, 8, 1382-1392.	1.1	648
141	Proximal Versus Distal Embolic Protection for Carotid Artery Stenting. JACC: Cardiovascular Interventions, 2015, 8, 609-615.	1.1	43
142	What's a Doctor to Do? Balloon, Stents, Drugs, Drills, andÂTreadmills. JACC: Cardiovascular Interventions, 2015, 8, 1113-1114.	1.1	3
143	One-Year Outcomes Following Directional Atherectomy of Infrapopliteal Artery Lesions. Journal of Endovascular Therapy, 2015, 22, 839-846.	0.8	48
144	Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial. American Heart Journal, 2015, 169, 479-485.	1.2	16

#	Article	IF	CITATIONS
145	The first 10 years of the American Board of Vascular Medicine. Vascular Medicine, 2015, 20, 69-73.	0.8	8
146	S.M.A.R.T. Self-Expanding Nitinol Stent for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (STROLL): 1-Year Outcomes. Journal of Vascular and Interventional Radiology, 2015, 26, 21-28.	0.2	59
147	Carotid Artery Intima-Media Thickness Measurements in the Youth: Reproducibility and Technical Considerations. Journal of the American Society of Echocardiography, 2015, 28, 309-316.	1.2	14
148	Accreditation status and geographic location of outpatient vascular testing facilities among Medicare beneficiaries: The VALUE (Vascular Accreditation, Location & Utilization Evaluation) Study. Vascular Medicine, 2014, 19, 376-384.	0.8	13
149	Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: impact on neointimal proliferation and healing. Open Heart, 2014, 1, e000117.	0.9	103
150	Core content for training in venous and lymphatic medicine. Phlebology, 2014, 29, 587-593.	0.6	11
151	Inferior Vena Cava Filter Usage, Complications, and Retrieval Rate in Cancer Patients. American Journal of Medicine, 2014, 127, 1111-1117.	0.6	35
152	Thrombolysis for Pulmonary Embolism and Risk of All-Cause Mortality, Major Bleeding, and Intracranial Hemorrhage. JAMA - Journal of the American Medical Association, 2014, 311, 2414.	3.8	602
153	The Systolic Blood Pressure Difference Between Arms and Cardiovascular Disease in the Framingham Heart Study. American Journal of Medicine, 2014, 127, 209-215.	0.6	112
154	Non-Invasive Carotid Imaging. Interventional Cardiology Clinics, 2014, 3, 13-20.	0.2	1
155	<sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Enables the Detection of Recurrent Same-Site Deep Vein Thrombosis by Illuminating Recently Formed, Neutrophil-Rich Thrombus. Circulation, 2014, 130, 1044-1052.	1.6	40
156	Lower Extremity Revascularization Using Directional Atherectomy. JACC: Cardiovascular Interventions, 2014, 7, 923-933.	1.1	210
157	The impact of prolonged lower limb ischemia on amputation, mortality, and functional status: The FRIENDS registry. American Heart Journal, 2014, 168, 577-587.	1.2	31
158	PAD Is No Longer Related to Rodney. Journal of the American College of Cardiology, 2014, 63, 691-692.	1.2	0
159	Drug-eluting Balloons: Are These Failed Solutions for the Treatment of Below-the-knee Peripheral Artery Disease?. Annals of Vascular Surgery, 2014, 28, 1078-1079.	0.4	3
160	Human type I pancreatic elastase treatment of arteriovenous fistulas in patients with chronic kidney disease. Journal of Vascular Surgery, 2014, 60, 454-461.e1.	0.6	45
161	Effect of Delayed Inferior Vena Cava Filter Retrieval After Early Initiation of Anticoagulation. American Journal of Cardiology, 2014, 113, 389-394.	0.7	28
162	Vascular Health in Kawasaki Disease. Journal of the American College of Cardiology, 2013, 62, 1114-1121.	1.2	46

#	Article	IF	CITATIONS
163	Clinical Manifestations of Fibromuscular Dysplasia Vary by Patient Sex. Journal of the American College of Cardiology, 2013, 62, 2026-2028.	1.2	80
164	Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Lesions. Journal of the American College of Cardiology, 2013, 61, 2417-2427.	1.2	307
165	Response to Letters Regarding Article, "Supervised Exercise Versus Primary Stenting for Claudication Resulting From Aortoiliac Peripheral Artery Disease: Six-Month Outcomes From the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) Study― Circulation, 2012, 126, .	1.6	0
166	Significant reduction in systolic blood pressure following renal artery stenting in patients with uncontrolled hypertension: Results from the HERCULES trial. Catheterization and Cardiovascular Interventions, 2012, 80, 343-350.	0.7	87
167	Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension. Circulation, 2011, 123, 1788-1830.	1.6	1,842
168	Two-year Clinical Evaluation of the Zilver Vascular Stent for Symptomatic Iliac Artery Disease. Journal of Vascular and Interventional Radiology, 2010, 21, 1489-1494.	0.2	12
169	Clinical Outcomes and Medical Care Costs Among Medicare Beneficiaries Receiving Therapy for Peripheral Arterial Disease. Annals of Vascular Surgery, 2010, 24, 577-587.	0.4	73
170	The Massachusetts General Hospital Vascular Center: Emergence of a Multidisciplinary Program Designed to Improve Quality Outcomes for Patients. Hospital Practice (1995), 2009, 37, 22-32.	0.5	0
171	Anti-Chlamydial Antibiotic Therapy for Symptom Improvement in Peripheral Artery Disease. Circulation, 2009, 119, 452-458.	1.6	32
172	Chronically anticoagulated patients who need surgery: Can lowâ€molecularâ€weight heparins really be used to "bridge―patients instead of intravenous unfractionated heparin?. Catheterization and Cardiovascular Interventions, 2009, 74, S17-21.	0.7	7
173	Response to Letter by Altieri et al. Stroke, 2009, 40, .	1.0	0
174	Imaging the Carotid Bifurcation: Toward Standardization. Seminars in Vascular Surgery, 2008, 21, 73-79.	1.1	5
175	Imaging of the carotid arteries: the role of duplex ultrasonography, magnetic resonance arteriography, and computerized tomographic arteriography. Vascular Medicine, 2008, 13, 281-292.	0.8	124
176	Response to Letter Regarding Article, $\hat{a} \in \infty$ The United States Preventive Services Task Force Recommendation Statement on Screening for Peripheral Arterial Disease: More Harm Than Benefit? $\hat{a} \in \mathbb{R}$ Circulation, 2007, 115, .	1.6	7
177	Does balloon angioplasty improve quality of life in patients with hypertension and renal artery stenosis?. Nature Clinical Practice Nephrology, 2006, 2, 18-19.	2.0	0
178	High utilization rate of vena cava filters in deep vein thrombosis. Thrombosis and Haemostasis, 2005, 93, 1117-1119.	1.8	34
179	Turf Wars: What Certification Brings to the Public and the Physician. The American Heart Hospital Journal, 2005, 3, 277-278.	0.2	0
180	Renal artery stenosis. Introduction. Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension, 2005, 23, S1-3.	0.1	0

#	Article	IF	CITATIONS
181	Renal artery stenosis. Conclusions. Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension, 2005, 23, S31-3.	0.1	O
182	Should All Coronary Angiographies Be Accompanied by a Renal Arteriogram (and Stent)?. Journal of Clinical Hypertension, 2004, 6, 513-515.	1.0	0
183	The Top 12 Advances in Vascular Medicine. Journal of Endovascular Therapy, 2004, 11, II-21-II-31.	0.8	2
184	Superficial Thrombophlebitis., 0,, 80-81.		0
185	Maffucci's Syndrome., 0,, 174-175.		O
186	Lipedema. , 0, , 96-97.		0
187	Klippel-Trenaunay Syndrome. , 0, , 160-161.		O
188	Reticular Veins., 0,, 76-77.		0
189	Glomus Tumor., 0,, 168-169.		O
190	Necrobiosis Lipoidica Diabeticorum., 0,, 120-121.		0
191	Sickle Cell Induced Leg Ulceration. , 0, , 124-125.		O
192	Milroy's Disease., 0,, 88-89.		0
193	Onychomycosis (Dermatophytic Onychomycosis)., 0,, 186-187.		O
194	Limb Ulceration Due to Malignant Melanoma. , 0, , 180-181.		0
195	Thalassemia Intermedia Induced Limb Ulceration. , 0, , 126-127.		O
196	Livedo Racemosa. , 0, , 40-41.		0
197	Telangiectasias., 0,, 74-75.		0
198	Lymphatic Malformations. , 0, , 162-163.		0

#	Article	IF	CITATIONS
199	Post-Traumatic Compartment Syndrome. , 0, , 26-27.		0
200	Ergotism. , 0, , 42-43.		0
201	Elephantiasis Nostras Verrucosa. , 0, , 94-95.		O
202	Hemangioma of Infancy. , 0, , 164-165.		0
203	Popliteal Cyst (Baker's Cyst)., 0,, 100-101.		0
204	Osler-Weber-Rendu Syndrome. , 0, , 176-177.		0
205	Trench Foot. , 0, , 140-141.		O
206	Gastrocnemius Muscle Rupture. , 0, , 104-105.		0
207	Yellow Nail Syndrome. , 0, , 92-93.		0
208	Frostbite., 0,, 136-137.		0